



Resistance to Therapy in Ovarian Cancers

Guest Editor:

Dr. Serena Bonin
DSM-Department of Medical
Sciences, University of Trieste,
34149 Trieste, Italy

Deadline for manuscript
submissions:

20 November 2024

Message from the Guest Editor

Dear Colleagues,

Ovarian cancers encompass a collection of neoplasms with distinct clinical–pathological, molecular features and prognosis. Most of them are epithelial tumors including high-grade serous ovarian cancers, endometrioid carcinomas, clear cell carcinomas, mucinous carcinomas, and low-grade serous ovarian cancers. Cytoreductive surgery followed by adjuvant platinum-based chemotherapy with or without maintenance therapy (bevacizumab or poly adenosine diphosphate ribosepolymerase (PARP) inhibitors) is the standard of care in most cases. Most patients are initially platinum sensitive, but soon after, they relapse. PARPi benefit patients with homologous recombination deficiency epithelial ovarian cancers by blocking the DNA repair pathways and inducing the apoptosis of cancer cells. However, similar to other chemotherapy agents, PARP inhibitors have different clinical indications and toxicity profiles, and 40–70% of patients experience drug resistance.

This Special Issue of IJMS will highlight the recent advances in understanding drug resistance in ovarian cancers. Experimental papers, up-to-date review articles, and commentaries are all welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI